TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06043362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 mg nicotine pouch
Description: Oral nicotine pouches that contain 0 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0 mg nicotine pouch
Description: Oral nicotine pouches that contain 0 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 mg nicotine pouch
Description: Oral nicotine pouches that contain 3 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 mg nicotine pouch
Description: Oral nicotine pouches that contain 3 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 mg nicotine pouch
Description: Oral nicotine pouches that contain 6 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 mg nicotine pouch
Description: Oral nicotine pouches that contain 6 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smooth nicotine pouch
Description: Non-flavored nicotine pouches that are characterized as smooth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smooth nicotine pouch
Description: Non-flavored nicotine pouches that are characterized as smooth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smooth nicotine pouch
Description: Non-flavored nicotine pouches that are characterized as smooth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wintergreen nicotine pouch
Description: Menthol flavored nicotine pouches that are characterized as wintergreen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wintergreen nicotine pouch
Description: Menthol flavored nicotine pouches that are characterized as wintergreen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wintergreen nicotine pouch
Description: Menthol flavored nicotine pouches that are characterized as wintergreen.
Study: NCT06057415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation
Description: Tactile-kinaesthetic and Oral sensorimotor Stimulation
Study: NCT06155786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) active stimulator
Description: In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial random noise stimulation (tRNS)
Description: Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) sham stimulator
Description: Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
Study: NCT04908813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX22
Description: IV Q3W D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX22
Description: IV Q3W D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IV Q3W D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV Q3W D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV Q3W D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: IV Q3W D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Q3W D1
Study: NCT06571292

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive training with robotic exoskeleton for upper limbs
Description: Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive training with robotic exoskeleton for upper limbs
Description: Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Task specific training
Description: Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Task specific training
Description: Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
Study: NCT06702189

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (sham)
Description: It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
Study: NCT06700603

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
Description: Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate，Every 2 weeks until disease progression or patient develops intolerable toxicity

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
Description: Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate，Every 2 weeks until disease progression or patient develops intolerable toxicity
Study: NCT05872958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3152
Description: AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3152
Description: AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3152
Description: AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3152
Description: AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3152
Description: AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
Study: NCT06702358

Intervention type: OTHER
Group type: OTHER
Intervention: Potential Therapeutic Implications of laser Acupoints on Visceral Fat and Hormonal Changes in Post-menopausal Women
Description: Application of laser acupuncture ( E M E ) on 10 acupuncture procedure for each woman which will be detected by therapist according to Acupuncture points Will stimulate St 25 (Tianshu), St 36 (Zusanli), Liv 3 (Taichong); P 6 (Neiguan), H 7 (Shenmen) for the psychical aspect of the therapy and Auriculothera- py: 55 (Shenmen) and 87 (Stomach) Each point stimulating will be Stimulation time, 30 s/point
Study: NCT06702267

Intervention type: DEVICE
Intervention: arterial blood samplers with needles PICO70 and safePICO syringes.
Description: PICO70 is a self-filling syringe for sample volumes in the range of 0.3-1.5 mL. All syringes are delivered with needle cube for safe needle disposal and a standard tip cap to reduce the risk of blood contact during blood mixing and sample transportation.~safePICO is a more advanced group of syringes based on the PICO70 family. They contain a gold coated magnetic steel ball facilitating automatic mixing of the blood when being used with the Radiometer ABL 90 with mixing module. The safePICO is a self-filling syringe covering a volume range of 0.7-1.5 mL and includes a vented safe tip cap (VTC), which simplifies removal of air bubbles and avoid the operator to get in contact with the blood, after attachment to the syringe. Some variants of safePICO are delivered with a needle shield device (NSD) to ensure safe removal of the needle.
Study: NCT06703827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The metacognitive training group
Description: The MCT will consist of spending 90 minutes a week in a small online group setting working through a series of workshops. Participants will also be asked to complete homework each week and they will be supported with this. Interviews and questionnaires regarding symptoms and thinking errors will be used before and immediately after the intervention. The participants who attended the group and improved in their symptoms and thinking errors will be invited to an interview asking them what worked for them and how they found the group.
Study: NCT06702527

Intervention type: PROCEDURE
Intervention: Mitral transcatheter edge-to-edge repair
Description: Mitral transcatheter edge-to-edge repair with the PASCAL system
Study: NCT06702943

Intervention type: DRUG
Intervention: Tigecycline (Tygacil)
Description: tigecycline-based regimen administered both intravenously (IV) and intraventricularly (IVT) for 14-21 days

Intervention type: DRUG
Intervention: Colistimethate sodium (CMS)
Description: Colistimethate sodium-based regimen (standard therapy for MDR infections) administered both IV and IVT for 14-21 days.
Study: NCT06702982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-nursing educational program
Description: The intervention administered in this study was a tele-nursing educational program aimed at improving cancer patients' management of chemotherapy-related symptoms and enhancing their quality of life. The program was delivered via a Telegram group, which provided a platform for regular interaction between the patients and nursing staff. The educational content was designed to address common chemotherapy-related symptoms, such as nausea, fatigue, pain, and loss of appetite, and to provide guidance on managing these symptoms effectively.
Study: NCT06702917

Intervention type: DEVICE
Intervention: GSI Cardiac Scan
Description: The investigational GSI Cardiac scan will take place immediately (back-to-back acquisition) following the single energy, non-GSI CCTA. The GSI Cardiac scan takes around 1 minute.~A subset of Cohort B's participants who are eligible due to a history of heart attack will have the investigational GSI Cardiac scan 10-15 minutes after the end of the CCTA scan.
Study: NCT05872958

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms.
Study: NCT05684120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Lifters for Undergraduates
Description: Participants will need to attend 14 hour-long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
Study: NCT06455098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMNYPULSE™ Catheter with the TRUPULSE Generator
Description: OMNYPULSE™ Catheter and TRUPULSE™ Generator will be used for PF ablation.
Study: NCT05266209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil skin care group
Description: No special technique was used for sample selection, random sample selection will be made. In the evaluation made according to the large effect size, the number of samples determined for Power: 0.80, :0.20 and :0.05 was determined as 66, with a minimum of 22 for each group. Calculations were made in computer environment using Power analysis (G\*Power 3.1.9.2) program. Random selection method will be used while creating research groups. Coconut oil, sunflower oil and control groups will be formed according to the order of admission to the unit. E.g; Coconut oil is planned for the first hospitalized newborn, sunflower oil for the second newborn, and third hospitalized newborn control group. This order will be repeated until a sufficient number of cases is reached when the newborns are included in the groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Coconut oil skin care group
Description: No special technique was used for sample selection, random sample selection will be made. In the evaluation made according to the large effect size, the number of samples determined for Power: 0.80, :0.20 and :0.05 was determined as 66, with a minimum of 22 for each group. Calculations were made in computer environment using Power analysis (G\*Power 3.1.9.2) program. Random selection method will be used while creating research groups. Coconut oil, sunflower oil and control groups will be formed according to the order of admission to the unit. E.g; Coconut oil is planned for the first hospitalized newborn, sunflower oil for the second newborn, and third hospitalized newborn control group. This order will be repeated until a sufficient number of cases is reached when the newborns are included in the groups.
Study: NCT06702917

Intervention type: DEVICE
Intervention: GSI Cardiac Scan
Description: The investigational GSI Cardiac scan will take place immediately (back-to-back acquisition) following the single energy, non-GSI CCTA. The GSI Cardiac scan takes around 1 minute.~A subset of Cohort B's participants who are eligible due to a history of heart attack will have the investigational GSI Cardiac scan 10-15 minutes after the end of the CCTA scan.

Intervention type: OTHER
Intervention: Standard of Care CCTA
Description: The standard of care scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.

Intervention type: OTHER
Intervention: Research CCTA
Description: The research scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
Study: NCT06702670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Diphenhydramine
Description: Diphenhydramine 50mg IV will be administered within 1 hour of the cervical exam which diagnosed prolonged active phase of labor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive cervical exams every 2 hours in active labor, placement of intrauterine pressure catheter, up titration of Pitocin if contractions are inadequate, maternal repositioning, and use of adjunct devices such as a peanut ball.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive cervical exams every 2 hours in active labor, placement of intrauterine pressure catheter, up titration of Pitocin if contractions are inadequate, maternal repositioning, and use of adjunct devices such as a peanut ball.
Study: NCT06703554

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sage Oil Mouthwash
Description: Sage oil obtained from a local market of herbal products in Egypt. In order to identify chemical composition of sage essential oils and overall purity, Gas Chromatography/ Mass Spectrometry analysis (GC/MS) performed

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chlorohexidine Mouthwash
Description: 0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, and sodium saccharin
Study: NCT06703008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEE hemodynamic monitoring
Description: Transesophageal echocardiography monitoring to guide administration of fluids, vasopressor and inotropes during liver transplantation in order to avoid hypotension.
Study: NCT05042687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m sestamibi
Description: Given by IV
Study: NCT06117111

Intervention type: DEVICE
Intervention: PaMo monitoring device
Description: Comparison of the device to standard monitoring
Study: NCT04639310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN496
Description: XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
Study: NCT05429632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mocravimod
Description: S1PR modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mocravimod
Description: S1PR modulator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mocravimod
Description: S1PR modulator
Study: NCT05183230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WellPATH-PREVENT
Description: WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimized WellPATH-PREVENT
Description: The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
Study: NCT06132412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
Study: NCT04908813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Q3W D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV Q3W D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO Q3W D1-D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO Q3W D1-D14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: PO Q3W D1-D14
Study: NCT06132412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: physical therapy
Description: Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
Study: NCT04932265

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HRG80™ Red Ginseng
Description: Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HRG80™ Red Ginseng + gamma cyclodextrin
Description: Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
Study: NCT04335877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Private sector component + modified BCC
Description: Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
Study: NCT01713803

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine and naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine and naloxone
Study: NCT04961333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Rehabilitation
Description: Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
Study: NCT04452344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid-containing analgesic
Description: hydrocodone/ acetaminophen combination product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: two over-the-counter analgesics
Description: combination of over-the-counter analgesics (ibuprofen/acetaminophen)
Study: NCT06572904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoxicam Injectable Product
Description: (EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly
Description: \* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly
Description: \* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)
Study: NCT06161376

Intervention type: OTHER
Intervention: S1P level
Description: Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.